| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.10. | Pila Pharma AB: Pila Pharma: First Subjects Dosed In Safety Part 1 Of PP-CT04, A Clinical Trial In People Living With Obesity | 446 | GlobeNewswire (Europe) | 12 October 2026, Malmö, Sweden: PILA PHARMA AB (publ)(FN STO: PILA)(FRA: 5KC), a clinical stage biotech company pioneering development of an oral TRPV1 antagonist as a potential first-in-class treatment... ► Artikel lesen | |
| 27.08. | PILA PHARMA AB H1 Loss Narrows | 4 | RTTNews | ||
| 27.08. | Pila Pharma AB: Pila Pharma Publishes Interim Report (1 January - 30 June 2026) | 802 | GlobeNewswire (Europe) | 27 August 2026: PILA PHARMA AB (publ) (FN STO: PILA), a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes... ► Artikel lesen | |
| 19.05. | Pila Pharma AB: Report From Pila Pharma Ab's Annual General Meeting 2026 | 259 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) held its Annual General Meeting today, Tuesday 19 May 2026, at the company's premises at Norra Vallgatan 72 in Malmö. Attorney Krister Hjelmstedt was elected as chairman of the... ► Artikel lesen | |
| PILA PHARMA Aktie jetzt für 0€ handeln | |||||
| 16.04. | Pila Pharma AB: Update To Preclinical Rat Obesity Studies - Low Exposure Of Xen-d0501 Could Explain Lack Of Effect On Bodyweight | 413 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug exposure in the obese rat studies... ► Artikel lesen | |
| 10.02. | Pila Pharma AB: Pila Pharma today publishes the Company's year-end report for the period January - December 2025. | 365 | GlobeNewswire (Europe) | The report can be found on the Company's website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
Operating income amounted to... ► Artikel lesen | |
| 26.01. | Pila Pharma AB: Pila Pharma Signs With New Clinical Cro To Prepare For Clinical Phase In Obesity After Preclinical Obesity Studies | 535 | GlobeNewswire (Europe) | Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,070 | -0,40 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,900 | 0,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 300,67 | -3,29 % | Praxis Precision Medicines: B.Riley initiiert Coverage mit "Buy" - Zulassungsentscheidungen rücken näher | ||
| DYNE THERAPEUTICS | 15,500 | -3,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 13,600 | 0,00 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| CG ONCOLOGY | 79,58 | -2,83 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| TARSUS PHARMACEUTICALS | 73,01 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ABSCI | 7,510 | 0,00 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus | ||
| TREVI THERAPEUTICS | 13,350 | 0,00 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 9,970 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| MBX BIOSCIENCES | 49,550 | -7,23 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,490 | +0,17 % | Enliven Therapeutics auf der Jefferies-Konferenz: Fokus auf CML-Pivotalstudie und solide Liquidität | ||
| KYMERA THERAPEUTICS | 115,27 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,445 | 0,00 % | Recursion CEO details novel Phase III endpoint for rare disease drug | ||
| EVOTEC | 2,506 | -8,21 % | Evotec-Aktie mit -95% - lohnt sich jetzt der Einstieg? | Die Evotec-Aktie ist am Freitag um -5,06% auf 2,97 € gefallen und bleibt damit fest in der Hand der Verkäufer. Der Kurs bewegt sich inzwischen am unteren Rand des langfristigen Abwärtstrendkanals und... ► Artikel lesen |